Asia-Pacific journal of clinical oncology最新文献

{"title":"A Case of Nivolumab-Related Myasthenia Gravis With Pretreatment Positive Anti-Acetylcholine Receptor Antibodies, and a Literature Review.","authors":"Minami Takahashi, Junji Kato, Taro Saito, Kohei Horimoto, Yoshiyuki Matsui, Masaya Tanno, Hisashi Uhara","doi":"10.1111/ajco.14193","DOIUrl":"https://doi.org/10.1111/ajco.14193","url":null,"abstract":"","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144131850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Surgery in Management of Primary Metastatic Endometrial Cancer.","authors":"Taylor Hodge, Monica McGauran, Antonia Jones, Rosemary McBain, Simon Hyde","doi":"10.1111/ajco.14188","DOIUrl":"https://doi.org/10.1111/ajco.14188","url":null,"abstract":"<p><p>For the majority of patients with endometrial cancer who are diagnosed at an early stage, high-quality evidence directs mainstay initial surgical treatment, which confers excellent long-term survival. Conversely, the 8%-15% of endometrial cancers diagnosed at a clinically advanced stage with primary metastatic disease have a significantly worse prognosis and a 5-year relative survival rate of 15%-20%. The management of primary advanced endometrial cancer is understudied with the majority of relevant evidence being retrospective, single institution, and in heterogenous populations (combined with management of recurrent endometrial cancer), and there are few prospective studies that focus solely on primary advanced disease. It appears that hysterectomy and surgical cytoreduction may improve long-term survival in metastatic endometrial cancer; however, it remains unclear which patients are most likely to benefit. Furthermore, the new integration of molecular classifications to the management of endometrial cancer has opened up new prognosis and treatment perspectives; however, the majority of current trials investigating new management paradigms based on molecular features exclude advanced-stage disease, so the implications for practice regarding this patient group are understudied. This review analyzes the current available evidence regarding surgical management of primary metastatic endometrial cancer, including current international guideline recommendations, evidence for primary cytoreductive surgery and neoadjuvant systemic treatment followed by surgery, surgical resection of distant metastases, and lymph node management.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144135975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognosis of Invasive Lobular Carcinoma and Effectiveness of Eribulin in Clinical Practice: A Post Hoc Analysis of a 2-Year Post-Marketing Surveillance.","authors":"Yuko Tanabe, Kenichi Inoue, Masato Takahashi, Hirofumi Mukai, Takashi Yamanaka, Chiyomi Egawa, Yohei Uchida, Yoichi Higashibeppu, Yukinori Sakata, Michiko Sugawara, Junji Tsurutani","doi":"10.1111/ajco.14189","DOIUrl":"https://doi.org/10.1111/ajco.14189","url":null,"abstract":"<p><strong>Aim: </strong>Invasive lobular carcinoma (ILC) is the second most common breast cancer type after invasive ductal carcinoma (IDC). Eribulin mesylate (eribulin) is a non-taxane microtubule dynamics inhibitor approved for advanced or metastatic breast cancer, including ILC and IDC. However, real-world data from eribulin-treated patients with advanced or metastatic ILC are scarce.</p><p><strong>Methods: </strong>This post hoc analysis of a Japanese multicenter, prospective, observational post-marketing surveillance (ClinicalTrials.gov: NCT02371174) evaluated data from eribulin-treated patients with ILC or IDC. Overall survival (OS) from the initiation of first-line chemotherapy, OS from the first date of eribulin administration, and time-to-treatment failure (TTF) were evaluated. OS from eribulin initiation was also evaluated by line of eribulin treatment (first-line, second-line, and third-line or later). Adverse drug reactions (ADRs) with ≥ 5% frequency in both groups were evaluated.</p><p><strong>Results: </strong>Among patients with ILC (n = 33) and IDC (n = 543), median OS from the initiation of first-line chemotherapy was 25.5 and 39.0 months, respectively (hazard ratio 1.94 [95% confidence interval 1.28-2.94]; p < 0.05), median OS from the first date of eribulin administration was 16.0 and 18.0 months, respectively (1.31 [0.87-1.97]), and TTF was 6 and 5 months (0.92 [0.65-1.32]). No significant differences were observed in median OS when stratified by line of eribulin treatment. Type and frequency of ADRs did not differ significantly between the groups.</p><p><strong>Conclusion: </strong>OS and TTF after eribulin initiation were similar between ILC and IDC cases, suggesting that eribulin might be a beneficial treatment option for ILC.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144126426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-Therapeutic Dosimetry of Metastatic Castration-Resistant Prostate Cancer With ¹⁷⁷Lu-PSMA: Experiences From Two University-Based Hospitals in Thailand.","authors":"Onnicha Pattanawong, Putthiporn Charoenphun, Wichana Chamroonrat, Thonnapong Thongpraparn, Nucharee Poon-Iad, Benjapa Khiewvan, Krisanat Chuamsaamarkkee","doi":"10.1111/ajco.14187","DOIUrl":"https://doi.org/10.1111/ajco.14187","url":null,"abstract":"<p><strong>Objective: </strong>¹⁷⁷Lu-PSMA radioligand therapy (RLT) is increasingly used to treat metastatic castration-resistant prostate cancer (mCRPC). Posttreatment dosimetry is essential for assessing normal organ absorbed doses. Therefore, this study aims to evaluate normal organs dosimetry in mCRPC patients undergoing ¹⁷⁷Lu-PSMA-RLT from two university-based hospitals in Thailand.</p><p><strong>Methods: </strong>We retrospectively analyzed 61 treatment cycles in 36 patients who underwent posttreatment whole-body planar imaging at three time points (1, 24, and 168 h postadministration). Absorbed doses were computed using organ based MIRD (Medical Internal Radiation Dosimetry) method with OLINDA/EXM v.2.2 in Hermes dosimetry software.</p><p><strong>Results: </strong>The median treated activity was 5.79 GBq (range 5.00-7.29 GBq). Normal organ absorbed doses, from lowest to highest, were red marrow (0.03 ± 0.03 Gy/GBq), total body (0.04 ± 0.03 Gy/GBq), liver (0.13 ± 0.33 Gy/GBq), salivary glands (0.65 ± 0.42 Gy/GBq), and kidneys (0.72 ± 0.36 Gy/GBq).</p><p><strong>Conclusion: </strong>Absorbed doses to normal organs remained within an acceptable range and not exceed the tolerance limits.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144109527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management Strategies and Outcomes of Tumor Thrombus in Extremity Osteosarcoma.","authors":"Ashik A Bary, Karthigaiselvi Murugesan, Chandra Kumar Krishnan, Shirley SunderSingh, Anand Raja","doi":"10.1111/ajco.14190","DOIUrl":"https://doi.org/10.1111/ajco.14190","url":null,"abstract":"<p><p>Osteosarcoma, accounting for 2.4% of all childhood malignancies and about 20% of primary bone cancers, primarily affects young adults, with 60% of cases occurring before age 25. Tumor thrombus (TT) formation, a type of cancer-associated thrombosis, is a rare but critical complication in osteosarcoma, leading to increased morbidity and mortality. TT is characterized by the direct extension of the tumor into adjacent vessels, displaying similar imaging characteristics and contrast enhancement as the primary tumor. Our study is a case series of five cases of extremity osteosarcoma where the presence of tumor thrombus has been diagnosed, highlighting diagnostic challenges and management strategies. Preoperative identification of TT remains difficult and is often diagnosed postoperatively or at autopsy. Advanced imaging techniques such as Computed Tomography, Magnetic Resonance Imaging, and Positron Emission Tomography can aid in the detection of TT, although they are not definitive. Surgical resection combined with thrombectomy is recommended, improving prognosis. Anticoagulation therapy aims to prevent bland thrombus formation rather than resolving TT, as the latter increases the risk of embolization. This study underscores the need for heightened suspicion and comprehensive preoperative imaging to improve outcomes in osteosarcoma patients with TT, advocating for multidisciplinary management including vascular surgeons during limb salvage procedures. Further research is essential to optimize anticoagulation protocols and validate these findings in larger cohorts.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144092772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is the Incidence of Early-Onset Adenocarcinomas in Aotearoa New Zealand Increasing?","authors":"Raymond Phang, Oliver Waddell, William Dixon, John Pearson, Andrew McCombie, Frank Frizelle","doi":"10.1111/ajco.14184","DOIUrl":"https://doi.org/10.1111/ajco.14184","url":null,"abstract":"<p><strong>Aim: </strong>The incidence of certain cancers in those under 50 years old (early-onset cancers) has been rising in many countries. This increase is generally unexplained and has significant implications for health policies and treatment. We wish to understand if this trend is occurring in Aotearoa New Zealand and whether it is across the spectrum of adenocarcinomas or site (cancer location)-specific. Differences in patterns between sites would suggest different possible etiologies for any increase in incidence and hence differences in how this trend might be managed.</p><p><strong>Method: </strong>The change in incidence of esophageal, gastric, colorectal, pancreatic, breast, lung, uterine, ovarian, and prostate adenocarcinomas from 2000 to 2020 in Aotearoa New Zealand was analyzed. Data was extracted from the New Zealand Cancer Registry. All new cases of relevant adenocarcinomas were analyzed to calculate the crude incidence, incidence rate ratios (IRRs), and age-standardized incidence. Trends were estimated by age and ethnicity, focusing on early-onset adenocarcinomas.</p><p><strong>Results: </strong>There was evidence for increases in early-onset colorectal (IRR 1.23, p < 0.01), breast (IRR 1.08, p < 0.01), uterine (IRR 1.73, p < 0.01), and prostate adenocarcinomas (IRR 1.14, p < 0.05). In Māori, there was evidence for significant increases in colorectal (IRR 1.42, p < 0.01), uterine (IRR 1.98, p < 0.01), and lung adenocarcinomas (IRR 1.23, p < 0.05).</p><p><strong>Conclusion: </strong>From 2000 to 2020, there were increases in multiple early-onset adenocarcinomas. This is site-specific, namely colorectal, breast, uterine, and prostate. Ongoing research is needed to investigate possible causes and develop strategies to address the increase in site-specific early-onset adenocarcinoma incidence.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144092695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multidisciplinary Implementation of Neoadjuvant Therapy for Early Breast Cancer in a Middle-income Country-Real-world Challenges in Malaysia.","authors":"Nur Aishah Mohd Taib, Nur Fadhlina Abdul Satar, Adibah Ali, Chun Sen Lim, Rohaizak Muhammad, Navarasi S Raja Gopal, Yueh Ni Lim, Shantini Arasaratnam, Juliana Abdul Latiff, Anita Baghawi, Char Hong Ng, Mastura Md Yusof","doi":"10.1111/ajco.14185","DOIUrl":"https://doi.org/10.1111/ajco.14185","url":null,"abstract":"<p><strong>Aim: </strong>Neoadjuvant therapy (NAT) is not widely employed for the management of patients with early breast cancer (EBC) in Malaysia. We sought to identify barriers to NAT and explore solutions for improving equitable, safe, and timely access to NAT in these patients.</p><p><strong>Methods: </strong>We used deliberative stakeholder consultation, a descriptive qualitative study design, for data collection. Sixteen breast cancer specialists (seven breast surgeons, seven clinical oncologists, one radiologist, and one pathologist) from 11 tertiary centers in Malaysia were purposively recruited. Deliberations were recorded, transcribed, and thematically analyzed to generate analytical and deliberative outputs. A literature search was performed to ensure that consensus statements were aligned with scientific evidence and clinical practice guidelines.</p><p><strong>Results: </strong>Four barrier themes affecting NAT implementation were derived: (1) diagnostic delays, (2) lack of access to oncology services, (3) patient low acceptance of NAT, and (4) high treatment costs. We highlighted potential solutions to address each barrier. Seven key areas for improvement were identified across the EBC care pathway: (1) rational use of imaging modalities, (2) biopsy sampling technique, (3) standardized histopathological reporting, (4) patient selection for NAT, (5) marker clip insertion, (6) monitoring during NAT, and (7) surgical axillary management. Expert recommendations for practice-change interventions were in alignment with published international, national, and institutional guidelines.</p><p><strong>Conclusion: </strong>Barriers to NAT in Malaysia are multifactorial. This study draws on a multidisciplinary stakeholder perspective to define real-world challenges faced by breast cancer specialists and provides recommendations for implementing guideline-recommended practices for NAT utilization in the local healthcare setting.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and Toxicity in Older Patients Receiving Anticancer Agents: A Retrospective Analysis of Australian Patients.","authors":"Joseph S Taylor, Cassandra White, Larissa Collins, Benjamin Moran, Craig Kukard","doi":"10.1111/ajco.14186","DOIUrl":"https://doi.org/10.1111/ajco.14186","url":null,"abstract":"<p><p>The number of older adults being treated for cancer is increasing. Despite this, older patients are under-represented in clinical trials. Those who are included are unlikely to be an accurate reflection of real-world patients as many are excluded based on performance status and comorbidities. There is a paucity of data examining the toxicity, and effectiveness, of systemic therapy in this group; particularly in a regional Australian cohort. Retrospective data from patients ≥75 years, on treatment for a solid organ malignancy in an Australian regional center was collected to assess the toxicity, and effectiveness, of immunotherapy and chemotherapy. Ninety-two patients were included. The mean age was 81. There was no significant difference in overall survival based on; age, Eastern Cooperative Oncology Group score, or number of comorbidities. Only 27% of treatments were ceased due to toxicity. 35% of patients on chemotherapy had had a dose reduction during treatment. Grade ≥3 toxicity was experienced by 32% of patients who received chemotherapy-containing regimens and 22% who received immunotherapy-containing regimens. To our knowledge, this is the first study providing real-world data on the effectiveness, and safety, of anti-cancer agents in older patients in a regional Australian center across multiple tumor streams. In older adults otherwise well enough for treatment, outcomes from treatment were not greatly affected by age. Other factors, rather than age and comorbidities alone, may predict outcomes. The use of screening tools may help select patients for comprehensive geriatric assessment.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143970364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Lung Cancer Patient Journey in Singapore: Challenges and Recommendations.","authors":"Lynette Teo, Mariko Siyue Koh, Kevin Lee Min Chua, Lowell Leow, Chong Hee Lim, Darren Wan-Teck Lim, Hong Liang Lim, Hwai Loong Kong, Gideon Ooi, Jens Samol, Chee Seng Tan, Ross A Soo","doi":"10.1111/ajco.14180","DOIUrl":"https://doi.org/10.1111/ajco.14180","url":null,"abstract":"<p><p>Early detection of lung cancer is crucial for improving survival rates because it allows for potentially curative treatments; however, most lung cancer cases in Singapore are diagnosed at advanced stages. This review article provides an overview of current practices in the management of early-stage non-small-cell lung cancer (stages I-IIIA) in Singapore (i.e., screening, diagnosis, treatment, and follow-up) while identifying and addressing the associated challenges. Implementing a locally adapted, subsidized national screening program with awareness campaigns can facilitate lung cancer screening uptake. Improving the accessibility and affordability of diagnostic tests and treatments, establishing clear referral pathways and diagnostic workup, adopting multidisciplinary teams, and utilizing cost-effective treatments are critical to timely and effective management of early-stage lung cancers. Establishment of local guidelines for follow-up care, integrating digital technologies and artificial intelligence, and expanding patient assistance programs for follow-up procedures are vital to improving long-term outcomes. Overall, improving the management of early-stage lung cancer necessitates collaboration among healthcare professionals, medical societies, policymakers, patient advocacy groups, and the general public.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143968044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survivorship Needs and Experiences of Survivors of Head and Neck Cancer in Rural Australia: A Qualitative Study.","authors":"Poorva Pradhan, Helen Hughes, Ashleigh R Sharman, Judith Lacey, Patrick Dwyer, Jacques Hill, Kimberley J Davis, Steven Craig, Raymond Wu, Bruce Ashford, Jenny Mitchell, Jonathan R Clark, Michael Elliott, Carsten E Palme, Rebecca L Venchiarutti","doi":"10.1111/ajco.14179","DOIUrl":"https://doi.org/10.1111/ajco.14179","url":null,"abstract":"<p><strong>Aim: </strong>Head and neck cancer (HNC) survivors experience complex survivorship needs compared to other cancer types. This is exacerbated for people living in regional and remote (rural) areas of Australia, who experience poorer outcomes, higher physical and psychological needs, and poorer quality of life compared to their metropolitan counterparts. Little is known about the general survivorship experiences of rural HNC survivors in New South Wales (NSW), Australia. This study aims to explore the general survivorship experiences of people living with HNC in rural areas of NSW, Australia.</p><p><strong>Methods: </strong>HNC survivors living in rural NSW were recruited, and semi-structured interviews were conducted to explore their general survivorship experiences. The interviews were recorded, transcribed, and analyzed using a qualitative thematic analysis approach until saturation of themes was reached.</p><p><strong>Results: </strong>Semi-structured interviews were conducted with 17 participants, with a mean age of 65 years. The most common diagnoses were oral cavity (41%) and oropharyngeal cancers (29%). Six key themes emerged around general survivorship experiences among participants: 1) financial impacts, 2) physical effects, 3) psychosocial effects, 4) clinical management, 5) information and support needs, and 6) access.</p><p><strong>Conclusions: </strong>Rural cancer survivors face unique survivorship concerns, exacerbated by living further from specialist care. The unmet needs of people living in rural areas include financial reimbursement, psychosocial services and support, and access to survivorship care closer to home. Understanding cancer survivors' experiences throughout the care journey can identify unmet needs. By recognizing these needs, they can be more readily addressed by government policy and other interventions.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143963592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}